usa today tirzepatide Eli Lilly telehealth partners continue to sell compounded GLP-1 weight-loss drugs despite agreement not to Lilly, Novo Fight Weight Loss
Description
The problem
Continuous enrollment requirements might introduce immortal time bias as outcomes for patients with less than 12 months of follow-up are not included, and selection bias might arise from including only patients with available laboratory results and EHRs
If I have any questions
*New England Journal of Medicine*, 387(3), 205216
Peptides are short chains of amino acids the building blocks of proteins
If you experience serious side effects, contact your prescriber promptly.
